Results 11 to 20 of about 3,302 (197)

Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis

Rheumatology and Therapy, 2022
Plain Language Summary Clinical trials in rheumatoid arthritis recruit too few patients from diverse ethnic backgrounds to be able to identify differences in treatment outcomes.
Bernard Combe, Robin Besuyen, Antonio Gómez-Centeno, Tsukasa Matsubara, Juan José Sancho Jimenez, Zhaoyu Yin, Maya H. Buch   +6 more
doaj   +4 more sources

Filgotinib in Active Noninfectious Uveitis [PDF]

JAMA Ophthalmology
ImportanceNoninfectious uveitis is a leading cause of visual impairment with an unmet need for additional treatment options.ObjectiveTo assess the efficacy and safety of filgotinib, a Janus kinase 1 (JAK1) preferential inhibitor, for the treatment of noninfectious uveitis.Design, Setting, and ParticipantsThe HUMBOLDT trial was a double-masked, placebo ...
Srivastava, Sunil K, Watkins, Timothy R, Nguyen, Quan Dong, Sharma, Sumit, Scales, David K, Dacey, Mark S, Shah, Rajiv E, Chu, David S, Grewal, Dilraj S, Faia, Lisa J, Suhler, Eric B, Genovese, Mark C, Guo, Ying, Barchuk, William T, Besuyen, Robin, Dick, Andrew D, Rosenbaum, James T   +16 more
openaire   +5 more sources

Filgotinib Radiographic and Clinical Efficacy Versus Other JAK Inhibitors and Adalimumab in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate: A Systematic Review and Network Meta-Analysis

Rheumatology and Therapy
A Bayesian network meta-analysis was conducted to examine the radiographic and clinical efficacy of the Janus kinase (JAK) inhibitors tofacitinib, baricitinib, upadacitinib, and filgotinib and the biologic disease-modifying antirheumatic drug (bDMARD ...
Yoshiya Tanaka, Rene Westhovens, Hong Sun, Carole Van der Donckt, Yan Zhong, Toshihiko Kaise   +5 more
doaj   +2 more sources

Optimal use and cycling strategies of Janus kinase inhibitors in ulcerative colitis: current evidence and clinical implications from the KASID Guidelines Task Force Team [PDF]

Intestinal Research
Janus kinase (JAK) inhibitors are an important treatment option for ulcerative colitis, providing rapid onset of action, oral administration, and efficacy even after biologic failure. The 3 approved agents—tofacitinib, filgotinib, and upadacitinib—differ
Seung Min Hong, Dong Hyun Kim, June Hwa Bae, Seung Yong Shin, Eun Mi Song, Ji Eun Kim, Young Joo Yang, Jiyoung Yoon, Sang-Bum Kang, Eun Soo Kim, Seong-Eun Kim, Seong-Jung Kim, Jun Lee, Soo-Young Na, Soo Jung Park, Sang Hyoung Park, Miyoung Choi, Myung Ha Kim, Won Moon, Sung-Ae Jung,   +20 more
doaj   +2 more sources

Filgotinib inhibits METTL3-mediated m6A of EIF3A by targeting ERG-TBP to suppress PDAC progression JAK-STAT3-independently [PDF]

npj Precision Oncology
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive tumor. EIF3A has been identified as a reader of N6-methyladenosine (m6A) modification, influencing the translation levels of various molecules and functioning as an oncogene.
Chaolei Zhang, Jianghao Ren, Kexiong Qiao, Chengjie Xu, Xiaofan Pu, Zongrong Chen, Liangjing Zhou, Liping Cao, Shengnan Jia   +8 more
doaj   +2 more sources

Filgotinib Is an Effective and Safe Treatment Option for Difficult-To-Treat Ulcerative Colitis: Real-World Evidence of the Dutch Initiative on Crohn and Colitis (ICC) Registry. [PDF]

United European Gastroenterol J
Background Filgotinib is a preferential Janus kinase 1 (JAK‐1) inhibitor registered for the treatment of ulcerative colitis (UC). Real‐world effectiveness of filgotinib, especially for difficult‐to‐treat (DTT, failure of ≥ 2 prior advanced therapies ...
Naber MR, van der Meulen AE, Voorneveld PW, Veltkamp SHC, van Bodegraven AA, Bodelier A, Mujagic Z, Pierik M, Verleye LMM, Duijvestein M, Bouwknegt DG, Visschedijk MC, Srivastava N, West RL, Oldenburg B, Löwenberg M, van Schaik FDM, Dutch ICC Registry.   +17 more
europepmc   +2 more sources

Preparation of colon-targeted pellets loaded with filgotinib/berberine hydrochloride and Their application in ulcerative colitis therapy. [PDF]

Int J Pharm X
Ulcerative colitis (UC) is a recurrent-remitting autoimmune disease of the colon, the pathogenesis of which remains incompletely understood. Recent studies have revealed gut dysbiosis and immune imbalance mediated by the JAK-STAT and NF-κB signaling ...
Wang J, Kuang Z, Chen B, Yan C, Shi B, Li G.   +5 more
europepmc   +2 more sources

Critical Appraisal of Filgotinib in the Treatment of Ulcerative Colitis: Current Evidence and Place in Therapy

Clinical and Experimental Gastroenterology, 2022
Arianna Dal Buono,1 Roberto Gabbiadini,1 Virginia Solitano,1,2 Edoardo Vespa,1,2 Tommaso Lorenzo Parigi,1,2 Alessandro Repici,2,3 Antonino Spinelli,1,2,4 Alessandro Armuzzi1,2 1IBD Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy ...
Antonino Spinelli, Alessandro Repici, Virginia Solitano   +2 more
exaly   +2 more sources

Rheumatoid Arthritis Preceded by Interstitial Lung Disease Controlled by Long‐Term Treatment With the Janus Kinase 1‐Selective Inhibitor, Filgotinib: A Case Report [PDF]

Respirology Case Reports
We present a case of active interstitial lung disease (ILD) preceding the onset of rheumatoid arthritis (RA). A 68‐year‐old man had dyspnea, decreased forced vital capacity, and elevated Krebs von den Lungen‐6 levels.
Takeo Sato, Shoko Nakazawa, Shotaro Yamamoto, Katsuya Nagatani, Kojiro Sato   +4 more
doaj   +2 more sources

Successful treatment of rheumatoid arthritis‐associated interstitial lung disease with filgotinib: A case report on janus kinase 1 inhibition

Respirology Case Reports
Filgotinib, a janus kinase 1 (JAK1) inhibitor, is used in the treatment of rheumatoid arthritis (RA). RA‐associated interstitial lung disease (RA‐ILD) is a severe RA complication with no established effective treatment.
Atsuhiko Sunaga
exaly   +2 more sources